BACKGROUND: Prior medication studies involving individuals with major depression in combination with an alcohol use disorder (MDD/AUD) have mainly focused on SSRI and tricyclic antidepressants, with generally ineffective results. Consequently, effective treatments for that common comorbid condition remain elusive. Mirtazapine is an antidepressant medicine with a unique pharmacological profile, whose effectiveness for treating non-comorbid depression reportedly may exceed that of SSRIs. OBJECTIVE/ METHODS: We now review the published literature regarding the tolerability and efficacy of mirtazapine for the treatment of the depression and the pathological alcohol ingestion of individuals with co-occurring MDD/AUD, including a review of four of our own small studies and two studies conducted outside the United States. RESULTS/ CONCLUSIONS: The findings of these studies suggest that mirtazapine is well tolerated among persons with comorbid MDD/AUD. Results also provide some evidence of efficacy for mirtazapine for decreasing the level of depression of persons with co-occurring MDD/AUD, and suggest that decreases in depression may occur relatively quickly after starting treatment, but provide no evidence of effectiveness for decreasing the level of alcohol ingestion. Large-scale double-blind, placebo-controlled studies are warranted to further clarify the tolerability and efficacy of mirtazapine among individuals with MDD/AUD.
BACKGROUND: Prior medication studies involving individuals with major depression in combination with an alcohol use disorder (MDD/AUD) have mainly focused on SSRI and tricyclic antidepressants, with generally ineffective results. Consequently, effective treatments for that common comorbid condition remain elusive. Mirtazapine is an antidepressant medicine with a unique pharmacological profile, whose effectiveness for treating non-comorbid depression reportedly may exceed that of SSRIs. OBJECTIVE/ METHODS: We now review the published literature regarding the tolerability and efficacy of mirtazapine for the treatment of the depression and the pathological alcohol ingestion of individuals with co-occurring MDD/AUD, including a review of four of our own small studies and two studies conducted outside the United States. RESULTS/ CONCLUSIONS: The findings of these studies suggest that mirtazapine is well tolerated among persons with comorbid MDD/AUD. Results also provide some evidence of efficacy for mirtazapine for decreasing the level of depression of persons with co-occurring MDD/AUD, and suggest that decreases in depression may occur relatively quickly after starting treatment, but provide no evidence of effectiveness for decreasing the level of alcohol ingestion. Large-scale double-blind, placebo-controlled studies are warranted to further clarify the tolerability and efficacy of mirtazapine among individuals with MDD/AUD.
Entities:
Keywords:
Alcohol use disorder; Comorbid; Major depression; Mirtazapine
Authors: Nadia Iovieno; Enrico Tedeschini; Kate H Bentley; A Eden Evins; George I Papakostas Journal: J Clin Psychiatry Date: 2011-04-19 Impact factor: 4.384
Authors: Jack R Cornelius; Antoine Douaihy; Oscar G Bukstein; Dennis C Daley; Scott D Wood; Thomas M Kelly; Ihsan M Salloum Journal: Addict Behav Date: 2011-04-09 Impact factor: 3.913
Authors: Jack R Cornelius; Antoine B Douaihy; Duncan B Clark; Dennis C Daley; Tammy A Chung; Maribeth A Wesesky; D Scott Wood; Ihsan Salloum Journal: J Addict Behav Ther Rehabil Date: 2013-08-24
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: D Bennabi; A Yrondi; T Charpeaud; J-B Genty; S Destouches; S Lancrenon; N Allaili; F Bellivier; T Bougerol; V Camus; O Doumy; J-M Dorey; F Haesebaert; J Holtzmann; C Lançon; M Lefebvre; F Moliere; I Nieto; C Rabu; R Richieri; L Schmitt; F Stephan; G Vaiva; M Walter; M Leboyer; W El-Hage; B Aouizerate; E Haffen; P-M Llorca; P Courtet Journal: BMC Psychiatry Date: 2019-01-30 Impact factor: 3.630